An observational study in Otorrhea, sponsored by Association Clinique Thérapeutique Infantile du val de Marne. Recruiting at 1 site in France. Open to participants aged 3 Months to 15 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Association Clinique Thérapeutique Infantile du val de Marne · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
After pneumococcal conjugate vaccine implementation, the number of acute otitis media (AOM) episodes has decreased, but AOM still remains among the most common diagnoses in childhood. From 2% to 17% of cases of AOM feature spontaneous perforation of the tympanic membrane (SPTM). The aim of this study was to describe the bacteriological causes of SPTM several years after PCV13 implementation, in 2010.
Since October 2015, children with spontaneous perforation of the tympanic membrane (SPTM) are prospectively enrolled by 20 pediatricians who are part of a research and teaching network (ACTIV, Association Clinique et Thérapeutique Infantile du Val de Marne [Clinical and Therapeutic Association of Val de Marne]) throughout France. For some patients, otorrhea is the first manifestation of AOM; for others, otorrhea occurred after AOM treatment failure or recurrence. Failure (non-responsive AOM) is defined as otorrhea appearing despite at least 48 hr of antibiotics or recurring less than 4 days after the end of antibiotic treatment. Recurrence is defined by the appearance of otorrhea 4 to 30 days after the end of antibiotic treatment for AOM.
Middle ear fluid (MEF) is obtained by sampling spontaneous discharge according to clinical practice guidelines. MEF specimens are obtained with cotton-tipped wire swabs, immediately placed in transport medium (Copan Venturi Transystem®, Brescia, Italy), and transported within 48 hr to one of the two centralized microbiology laboratories (Robert Debré Hospital or National Centre for Pneumococci at European Georges Pompidou Hospital, Paris, France).
Association Clinique Thérapeutique Infantile du val de Marne is the lead sponsor of 15 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
all children from 3 months to 15 years old with otorrhea
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Middle ear fluid sample for each enrrolled children
Other: middle ear fluid sample for bacterial analysis (conventional microbiology analysis)
A middle ear fluid sample will be collected from each enrolled child for the third analysis procedure.
Also known as: middle ear fluid sample for molecular sequencing analysis, middle ear fluid sample for Rapid Diagnostic Test (RDT)
Microbiological Profiles of Spontaneous Otorrhea in Children
To determine the microbiological profiles of spontaneous otorrhea in children by identifying the bacterial pathogens present in collected samples.
Time frame: at inclusion
Descriptive analysis of patient characteristics according to bacteriological Profiles
To describe, for each bacterial species identified, patient characteristics according to demographics, vaccinal and general medical history, AOM history, and sample collection conditions.
Time frame: at inclusion
Clinical Characteristics of Treatment Failure or Recurrence in Children with AOM
To describe the clinical characteristics of treatment failure or recurrence in children with acute otitis media (AOM), according to the identified bacteria, including symptom severity, duration, and observed clinical signs.
Time frame: at inclusion
Microbiota Analysis of Spontaneous Otorrhea in Children
To analyze the microbiota involved in spontaneous otorrhea and bacterial interactions using molecular biology techniques and compare these results with conventional bacteriological methods.
Time frame: at inclusion
Comparison Between Rapid Diagnostic Test (RDT) and Laboratory Results
To compare the results of the rapid diagnostic test (RDT) with those obtained from samples analyzed in the laboratory using standard bacteriological methods.
Time frame: at inclusion
Plan to share: Undecided
Started Oct 2015 (actual). Primary completion is estimated for Oct 2028, 156 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Association Clinique Thérapeutique Infantile du val de Marne